Program
NTQ6179
A development code.
In Sino Biopharmaceutical's pipeline, SSTR2
. Its studies are mostly in Acromegaly, led by Sino Biopharmaceutical.
Furthest: phase 1, since Oct 20, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Oct 20, 2026 | Oct 20, 2026 | Apr 2027phase 1 · NCT07909837 |
- Named in Sino Biopharmaceutical’s own pipeline as
NTQ6179
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2026First study: phase 1 study in AcromegalyFirst studyNCT07909837 · 56 planned · China
Ahead
- Apr 2027Primary completion: phase 1 study in AcromegalyNCT07909837
TargetBeta
“SSTR2”the company's pipeline, read by Claude · source
Other programs on SSTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Octreotiderule | Novartis | phase 4 | 36 |
| Paltusotinerule | Vertex Pharmaceuticals | phase 3 | 9 |
| actinium AC-225 dotatate | Bristol-Myers Squibb | phase 3 | 3 |
| SSTR2-targeting Non-peptide Drug Conjugate CRN09682rule | Vertex Pharmaceuticals | phase 2 | 1 |
| Actinium Ac 225 SSTR2-targeted Agent RYZ401 | Bristol-Myers Squibb | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07909837Acromegaly · China | 1 | Recruiting | Apr 2027 | 56 |
How it is read
Names in the registry
- “NTQ6179”, 1 entry
Codes read as this program: NTQ6179.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.